Advertisement
UK markets open in 4 hours 29 minutes

  • NIKKEI 225

    37,757.17
    -702.91 (-1.83%)
     

  • HANG SENG

    17,263.99
    +62.72 (+0.36%)
     

  • CRUDE OIL

    82.71
    -0.10 (-0.12%)
     

  • GOLD FUTURES

    2,331.50
    -6.90 (-0.30%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,603.38
    -1,817.61 (-3.40%)
     

  • CMC Crypto 200

    1,388.56
    -35.54 (-2.50%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

BUZZ-Top of the Street: IMI, Roche, Beazley, Coloplast

Reuters - UK Focus

A round-up of notable broker activity this morning from Europe's top-ranked* analysts:

** Jefferies upgrades IMI (LSE: IMI.L - news) to "buy" on attractive valuation due to recent share price underperformance; broker says sentiment towards co is overly negative at present and will unwind as management delivers in-line performance or better through the year

** Bernstein downgrades Swiss drugmaker Roche to "market-perform", saying consensus estimates are too high and biosimilar headwinds are likely to strengthen

** Numis cuts Beazley (LSE: BEZ.L - news) to "hold" on the back of recent strength in stock price after the company reported Q1 in line with brokerage forecasts

ADVERTISEMENT

** Berenberg raises Coloplast (LSE: 0QBO.L - news) to "hold" saying that co is now poised to take further market share over the coming years, delivering defensive top-line growth and perhaps even a little operational leverage

(*Analyst rankings from Thomson Reuters StarMine. Scale is from 1-star to 5-star with 5 being best. Analysts ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.)